Latest News and Press Releases

Dublin, Jan. 08, 2025 (GLOBE NEWSWIRE) -- The "Celiac Disease Treatment Market by Treatment, by Route of Administration, by Distribution Channel, and By Region" report has been added to ...

OXFORD, United Kingdom and GERMANTOWN, Md., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio”), today announced the promotion of Geoffrey Lynn, M.D.,...

Lead product AMYNOPEP achieves proof-of-principle in exploratory clinical studyAMYNOPEP is the first and only gluten-digesting enzyme combination that supports and enhances the activity of critical...

Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in...

Toronto, ON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- A recent survey conducted by Celiac Canada reveals that Canadian universities and colleges are not providing adequate gluten-free accommodations on...

Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results

BOCA RATON, Fla., July 31, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in...

Lewes, Delaware, July 18, 2024 (GLOBE NEWSWIRE) -- The Global Gluten Free Products Market Size is projected to grow at a CAGR of 7.20% from 2024 to 2031, according to a new report published by...

Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections